Lentigen and Dharmacon Pen shRNA Development Deal
Lentigen and Dharmacon last week said they plan to develop and manufacture lentiviral expression reagents to deliver short hairpin RNA expression vectors into cells using RNA interference-mediated gene silencing.
As part of the alliance Dharmacon will design reagents combined with Lentigen's high-titer LentiMax vector system to develop the lentiviral particles. Terms of the deal call for Lentigen to manufacture and for Dharmacon to sell the resulting products.
Financial details were not disclosed.
Thermo, Fisher Shareholders Approve Merger; Fisher Will Divest $17M Product Line to Satisfy FTC Request for Info Tied to Merger
Thermo Electron and Fisher Scientific International recently said that their shareholders have approved their merger.
The companies said that the deal remains subject to regulatory approval.
As originally expected, the $10.6 billion deal is scheduled to close by the end of the fourth quarter. The firms announced the deal in May.
In addition, Fisher said that it plans to divest an undisclosed product line after the Federal Trade Commission asked for information about that line as part of its review into Fisher’s planned merger with Thermo.
Fisher said the product line is worth $17 million.
According to Fisher, the FTC had asked that it and Thermo provide it with additional information about the line, which Fisher described as a “single, minor product line.”
Fisher said the FTC’s request is the second time the government agency has asked for information about the companies’ product lines.
“Thermo and Fisher expect to resolve issues raised by the second request by agreeing to divest a $17 million product line of Fisher's,” Fisher said in a statement.
Caden Biosciences Raises $5.9M in Series A Financing to Develop GPCR Screening Tech
Caden Biosciences this week said that it has closed a Series A financing round worth $5.85 million to develop GPCR screening assays for the pharmaceutical and biotech industries
Venture capital firm Baird Venture Partners led the financing round, which also included contributions from new investors Venture Investors, the State of Wisconsin Investment Board, and IllinoisVentures, and existing investor Vanderbilt University.
Pete Shagory of Baird and Paul Weiss, representing Venture Investors, will join Caden’s board of directors. The company also announced plans to relocate from Evanston, Ill., to Madison, Wis.
Cadus Biotech’s develops membrane-based biochemical assays for screening GPCR targets. The company was previously known as Cue Biotech.
Panasonic and Kalypsys to Co-Develop Drug-Discovery Tools
Japanese electronics manufacturer Panasonic and San Diego-based biotech Kalypsys this week said the companies would collaborate to develop “next-generation” drug-discovery systems.
The collaboration includes the development, production, and marketing of equipment and integrated systems that will allow researchers to address all aspects of drug discovery and life science research, the companies said in a statement.
Panasonic will lend its expertise in product manufacturing, engineering, and marketing, while Kalypsys will contribute its experience in developing integrated drug-discovery systems, the firms said.
Specific details about the drug-discovery systems to be produced were not disclosed.